Adaptimmune Therapeutics PLC (NAS:ADAP)
$ 0.7969 0.02 (2.57%) Market Cap: 203.80 Mil Enterprise Value: 36.36 Mil PE Ratio: 0 PB Ratio: 2.11 GF Score: 62/100

Full Year 2022 Adaptimmune Therapeutics PLC Earnings Call Transcript

Mar 06, 2023 / 01:00PM GMT
Release Date Price: $1.32 (-25.00%)
Operator

Welcome to Adaptimmune and TCR2 joint webcast to discuss their strategic combination announced earlier this morning.

I will turn the call over to Juli Miller, VP of Investor Relations and Corporate Affairs at Adaptimmune.

Juli?

Juli P. Miller
Adaptimmune Therapeutics plc - VP of Corporate Affairs & IR

Thank you, operator. Hello. Good morning. We issued a joint press release with TCR2 Therapeutics, announcing entry into an agreement for the strategic combination of our 2 companies. In the second press release, we provided our Q4 and full-year 2022 financial and business updates. I would ask you to review the full text of the forward-looking statements. We anticipate making projections during this webcast, and actual results could differ materially due to several factors, including those outlined in our latest filings with the SEC, as well as our 10-K filing for the year ended 2022, which will be filed later today. Of note, we will share slides during this webcast, which are also available on the presentations tab of our Investor Relations

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot